article thumbnail

Tranq dope (fentanyl-xylazine combination): A new horizon in opioid withdrawal treatment

ALiEM - Pharm Pearls

Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. 2024 study [16]. Prolonged QTc was defined as >450 msec.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NHC Comments on CMS 2026 Notice of Benefit and Payment Parameters

Putting Patients First Blog

Recognizing PrEP as a preventive service rather than as indicative of an active medical condition, as HHS proposes, could help address the current risk selection seen in the market. Clear guidance on the treatment of rebates within the ACF will help avoid distortions in pricing and prevent patients from bearing disproportionate costs.

article thumbnail

Year In Review: Top Infectious Diseases Articles From 2024

ID Stewardship

In this articlea selection of notable peer-reviewed publications from 2024 are provided. BCPS, BCIDP 2024 has been an interesting year forinfectious disease literature dissemination. As 2024 comes to a close, my friend Dr. We hope you find this list helpful, maybe it will even inspire a journal club or two! Gauthier, Pharm.D.,